Brought to you by 
Sobi gains exclusive US rights to AZ's Synagis; deal value tops $2.3bn
03 Dec 2018
Executive Summary
AstraZeneca PLC sold Swedish Orphan Biovitrum AB (Sobi) exclusive rights to commercialize the respiratory syncytial virus therapy Synagis (palivizumab) in the US. Sobi will also participate in AZ’s share of profits and losses related to another RSV therapy MEDI8897 (being developed in Phase II trials under a deal between AZ and Sanofi Pasteur.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sobi gains exclusive US rights to AZ's Synagis; deal value tops $2.3bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice